-
Sophiris slides on prostate cancer data but vows to press on
fiercebiotech
December 25, 2018
Sophiris Bio is adamant that it will advance its lead drug topsalysin into phase 3 testing, after a second dose showed no additional benefit in a prostate cancer trial.....
-
Bayer plans filings for prostate cancer drug darolutamide
pharmaphorum
December 20, 2018
Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson & Johnson have already gained a foothold.
-
Surgery May Benefit Some With Early Prostate Cancer: Study
drugs
December 13, 2018
?For certain men with early?prostate cancer, choosing surgery over "watchful waiting" may add a few years to their lives, a new study suggests.....
-
Canada clinical trial on personalised medicine for prostate cancer
europeanpharmaceuticalreview
November 29, 2018
A clinical trial could be the world’s first to look at personalised medicine in prostate cancer, with patients taking a therapy based on their DNA markers…
-
Researchers to trial prostate cancer saliva test
pharmatimes
July 10, 2018
An international team of researchers, led by scientists at The Institute of Cancer Research, London, are planning to trial a novel saliva-based DNA test designed to predict men at risk of developing prostate cancer.
-
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
pharmatimes
July 06, 2018
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
-
NICE says Tookad too expensive for prostate cancer
pharmatimes
July 04, 2018
The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
-
Keytruda offers significant hope in subset of prostate cancer
pharmafile
June 07, 2018
Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at ASCO, a team from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust were able to use MSD’s Keyt
-
Trial first to show immunotherapy benefit in prostate cancer
pharmatimes
June 06, 2018
An international trial led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has shown that immunotherapy can benefit men with prostate cancer.
-
Look out, J&J. Sun Pharma's Yonsa nod in prostate cancer puts Zytiga on notice
fiercepharma
May 28, 2018
Early this year, Johnson & Johnson prostate cancer blockbuster Zytiga took an unexpected hit when a U.S. court stripped away a key patent, opening the prospect of generic launches later this year—a prospect J&J is working hard to avoid
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
